ABSTRACT
Objective To observe the effect of of Jiuweiqianghuo pill combined with salmeterol fluticasone propionate on chronic obstructive pulmonary disease.Methods136 patientswith chronic obstructive pulmonary disease from January 2016 to December 2016 were grouped two groups by admission sequence.Two groups were treated with routine treatment and observation group was treated another with Jiuweiqianghuo pill to analyse its effect.ResultsThe total effective rate of observation group was 94.12%,higher than control group 79.41%(P<0.05).FEV1/ expected value and FEV1/FVC of observation group were(66.32±4.27),(71.15±4.41)%,higher than that of control group(58.37±4.19,65.16±4.30)%(P<0.05).6MWT and CAT score of observation group were(319.1±19.5m,19.15±2.97points),better than that of control group(287.4±18.0)m,(23.01±3.08)points(P<0.05).IL-8,TNF-α and hs-CRP level of observation group were(13.40±4.05)ng/L, (18.64±4.21)ng/L, (10.91±2.59)mg/L,lower than that of control group(18.92±4.27)ng/L, (25.13±4.48)ng/L, (14.67±2.75)mg/L(P<0.05).Adverse reactions rate of observation group was 2.94%,slightly lower than control group with 5.88%.ConclusionJiuweiqianghuo pill can decreased serum inflammation and improve lung function to improve the therapeutic effect of chronic obstructive pulmonary disease and it does not increase adverse reactions.
ABSTRACT
Objective To investigate the clinical effect of salmeterol fluticasone propionate combined with montelukast in the treatment of moderate and severe bronchial asthma. Methods 112 patients with moderate and severe bronchial asthma in Taizhou hospital from January 2014 to December 2016 were selected and divided into the control and the study group according to the time of visiting hospital, 56 cases in each group. The control group were given salmeterol fluticasone propionate for treatment, the study group were treated with salmeterol fluticasone propionate combined with montelukast .Keep a record of the asthma control test (ACT), forced expiratory volume (FEV1) percentage expected index changes of pre-treatment and 8 weeks after treatment. Results ACT score and FEV1 percentage expected index changes of two groups there was no significant difference before the treatment. After treatment, ACT score and FEV1 percentage expected index changes of the study group was better than the control group(P<0.05). Conclusion Salmeterol fluticasone propionate combined with montelukast in the treatment can significantly improve the clinical efficacy of patients.
ABSTRACT
Objective To investigate the clinical effect of salmeterol fluticasone propionate combined with montelukast in the treatment of moderate and severe bronchial asthma. Methods 112 patients with moderate and severe bronchial asthma in Taizhou hospital from January 2014 to December 2016 were selected and divided into the control and the study group according to the time of visiting hospital, 56 cases in each group. The control group were given salmeterol fluticasone propionate for treatment, the study group were treated with salmeterol fluticasone propionate combined with montelukast .Keep a record of the asthma control test (ACT), forced expiratory volume (FEV1) percentage expected index changes of pre-treatment and 8 weeks after treatment. Results ACT score and FEV1 percentage expected index changes of two groups there was no significant difference before the treatment. After treatment, ACT score and FEV1 percentage expected index changes of the study group was better than the control group(P<0.05). Conclusion Salmeterol fluticasone propionate combined with montelukast in the treatment can significantly improve the clinical efficacy of patients.
ABSTRACT
Objective:To observe the clinical effect and adverse reactions of salmeterol fluticasone propionate in the treatment of cough after infection to provide basis for the clinical treatment. Methods:Totally 324 patients with cough after infection were selected randomly divided into the control group and the treatment group with 162 cases in each. The control group was given routine therapy and the treatment group was treated with salmeterol fluticasone propionateon additionally. Daytime and night cough symptom scores were evaluated before and after the treatment,symptom disappearance time was recorded,and cough severity was assessed using visual analogue scale. The adverse reactions were observed as well. Results:The daytime and night cough symptom scores and visual analog score of the treatment group after the treatment were all lower than those of the control group after the treatment with statistically significant differences(P 0. 05). Conclusion:Salmeterol fluticasone propionate shows better clinical curative effect in the treatment of cough after infection,which can significantly improve the clinical symptoms of patients and shorten the time of symptoms improvement with high security and is worthy of clinical popularization and application.
ABSTRACT
Objective To evaluate the clinical efficacy of salmeterol /fluticasone propionate in the treatment of chronic obstructive pulmonary disease .Methods 107 patients with chronic obstructive pulmonary disease from June 2012 to June 2014 were randomly divided into control group and observation group .Patients in control group re-ceived routine therapy, yet patients in observation group received salmeterol /fluticasone propionate on the basis of routine therapy.The st.George respiratory questionnaire (SGRQ) mark, 6 -minwalktest (6MWT),pulmonary func-tion indexes and drug adverse reactions before treatment and after treatment were observed respectively .Results Af-ter treatment, the lung function index recovery , the SGRQ total score,6MWT of observation group was obviously bet -ter than that of the control group , and the difference had statistical significance (p 0.05).Conclusion On top of conventional therapy ,salmeterol /fluticasone propionate has good clinical curative effect and high safety for treating COPD,and so it is suitable for long -term and sustained treatment .
ABSTRACT
Objective To explore the effects of salmeterol/fluticasone propionate complicated or combined with N-acetylcysteine on the pulmonary function and arterial blood gas analysis of the patients with chronic obstructive pulmonary disease (COPD), and to evaluate its curative effect.Methods 84 cases of COPD patients were randomly divided into combination treatment group (n=44)and simple treatment group (n=40).The patients in combination treatment group were treated with salmeterol/fluticasone propionate combinated with N-acetylcysteine while the patients in simple treatment group were treated only with salmeterol/fluticasone propionate, both of which were followed up for 6 months.The changes of pulmonary function (FEV1%FVC,FEV1%Pred,PEF daily variation rate:ΔPEF%)and the arterial blood gas analysis indexes (PaO2 and PaCO2 )of the patients in two groups were recorded before treatment, 3 months after treatment, and 6 months after treatment. Results The FEV1%FVC,FEV1%Pred and PaO2 of the patients in combination treatment group and simple treatment group were obviously increased 3 and 6 months after treatment compared with before treatment (P0.05).TheΔPEF% of the patients in two groups had no significant differences between inter-group and intra-group before and after treatment (P > 0.05 ). Conclusion Combination of salmeterol/fluticasone propionate and N-acetylcysteine can obviously improve the pulmonary function and arterial blood gas analysis indexes of the COPD patients, which is superior to the simple application of salmeterol/fluticasone propionate and has definite and lasting curative effect on the treatment of COPD.
ABSTRACT
Objective:To investigate the efficacy and safety of 6 months inhalation of(SM/FP) among children.with moderate to severe asthma.Methods:145 children with moderate-severe asthma,aged between 4 and 14 years,were given SM/FP at the dose of 50/100?g twice daily in moderate group and 50/100?g 3 times every day in severe group for 6 months.The PEFam,symptom scores and the as-needed beta2 agonists were recorded at the beginning,2 weeks,1 month,2 months,4 months and 6 months after treatment.And the side effects were recorded also during the therapy.Results:Outcomes of clinical symptoms, PEFam and as-needed beta2 agomsts in all 145 cases improved significantly since 2 week ( P